Condition: Cervical Cancer · Sponsor: Tianjin Medical University Cancer Institute and Hospital
To explore the efficacy and tolerability of a platinum-based regimen combined with the PD-1 antibody toripalimab administered prior to concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
This description comes directly from the study's public registry record.
Jie Chen · +86-18622221202 · tjcjvip@126.com
Yuanjie Cao · +86-18522123151 · cyjro325@gmail.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Institute&Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07092696